


eye - light[®]

AND YOU ARE THE DRY-EYE SPECIALIST

Synergic treatments

OPE[®] + LIGHT MODULATION[®]



THE SOLUTION FOR DRY EYE DISEASE
... AND MORE

TWO PATENTED TECHNOLOGIES

CE
0476

eye - light®

AND YOU ARE THE DRY-EYE SPECIALIST

LIGHT MODULATION® / LLLT – LOW LEVEL LIGHT THERAPY

The beneficial effects of LLLT in medicine are widely recognized by Physicians and Surgeons: treating certain types of skin cancer, vitiligo, regeneration of gum tissue, etc. To be effective, the emission of light requires a specific wavelength and a proper distance in order to obtain a deep impact on the treated tissue. Cells absorb light photons and transform their energy into bio-chemical energy producing this way the metabolic processes required to repair and regenerate cells.

- ✓ **LIGHT MODULATION®** is a Patented photobiomodulation (PBM) technology, a **strong metabolic enhancer** that stimulates the production of ATP (Adenosine Triphosphate) to increase cellular action and emphasize cells activities.
- ✓ The LED emitting matrix **trigger eyelids endogenous heat, directly** stimulating the normalization of glands and supporting the thermal impact of the OPE® technology action.

OPE® OPTIMAL POWER ENERGY / IPL

OPE® is a Patented broad light spectrum technology that excludes all emissions which are not relevant to the treatment. It is based on a highly customizable technology, capable of optimizing the stimulation and regeneration of tissues.

The interaction of OPE® (IPL) technology with tissue is essentially thermal, and thanks to the embedded management software, it allows to optimize heat emission, stimulating the Meibomian glands to resume normal functionality.

- ✓ Thanks to the **patented** and unique cooling module, the **use of gel is not required**.
- ✓ A highly **intuitive software** allows the Operator to work at best and safely since the very first treatment, with automatic power adjustment and duration of each light impulse.
- ✓ **Largest treatment spot available** on the market: around 12 cm², up to **three times** over competition.

«WHY OPE® TECHNOLOGY IS BETTER THAN PULSED LIGHT TECHNOLOGY IPL ?»

“It is a technology in which wavelengths and energy of the emitted light are exploited at 100% in respect of metabolism of cells exposed to it. The absence of contact surfaces has raised considerably the safety margins for the Patient”.

Paolo Mezzana, MD

Specialist in Plastic, Reconstructive and Aesthetic Surgery (Rome, Italy)

Lecturer at the Department of Biomedical Studies, University of San Marino (II level Master Course in Medicine and Aesthetic Surgery)

University Teacher Foundation Fatebenefratelli (Rome, Italy)

Member of the American Society for Lasers in Medicine and Surgery - R&D International Society of Cosmetic Dermatology



EXCLUSIVE AND PATENTED TECHNOLOGIES TO OPTIMIZE THE ENERGY OF LIGHT AND HEAT

eye - light®

AND YOU ARE THE DRY-EYE SPECIALIST

The equipment treats the Meibomian glands of upper and lower eyelids with direct and indirect application of the two exclusive technologies.

- ✓ **LIGHT MODULATION®** treats directly the Meibomian glands inducing endogenous heat of both eyelids, increasing and stabilizing thus tear lipid layer.
- ✓ **OPE®** applied on periorbital and cheekbone areas, triggers stimulation of neurotransmitters. These solicit the Meibomian glands to produce, contracting, a higher secretion; the natural lipid flow increases reducing evaporation of tears.

ONE INSTRUMENT- MANY TREATMENTS



DRY-EYE



**AESTHETIC
MEDICINE**



**OPHTHALMIC
TREATMENTS**



UNIQUE

- TWO TECHNOLOGIES WORKING IN SYNERGY FOR OPTIMAL RESULTS: MEIBOMIAN GLAND'S **DIRECT AND INDIRECT TREATMENTS**

SAFE

- **PATENTED TECHNOLOGIES** USED IN MEDICINE AND SURGERY SINCE YEARS
- **MEDICAL CE CERTIFICATION FOR OPHTHALMOLOGY AND DERMATOLOGY**
- **FDA CERTIFICATION FOR DERMATOLOGY**
- **TGA HEALTH SAFETY REGULATION FOR OPHTHALMOLOGY AND DERMATOLOGY**

RAPID

- ONLY FEW MINUTES : 3' OPE® + 15' LIGHT MODULATION® - RESULTS AS OF **THE FIRST TREATMENT**

USER FRIENDLY

- SOFTWARE SETS PARAMETERS : **COMPLETELY AUTOMATIC**

1. CURR OPIN OPHTHALMOL. 2015 JUL; 26(4): 314-8. DOI: 10.1097/ICU.0000000000000166. - [INTENSE PULSED LIGHT THERAPY FOR THE TREATMENT OF EVAPORATIVE DRY EYE DISEASE](#). VORA GK, GUPTA PK.
2. INVEST OPHTHALMOL VIS SCI. 2015 FEB 12;56(3):1965-70. DOI: 10.1167/IOVS.14-15764. - [PROSPECTIVE TRIAL OF INTENSE PULSED LIGHT FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION](#). CRAIG JP, CHEN YH, TURNBULL PR.
3. PHOTOMED LASER SURG. 2015 JAN 1; 33(1): 41-46. - [INTENSE PULSED LIGHT TREATMENT FOR DRY EYE DISEASE DUE TO MEIBOMIAN GLAND DYSFUNCTION; A 3-YEAR RETROSPECTIVE STUDY](#). ROLANDO TOYOS, MD, WILLIAM MCGILL, PHD AND DUSTIN BRISCOE, OD.
4. PHOTOMEDICINE AND LASER SURGERY VOLUME 34, NUMBER 3, 2016 © MARY ANN LIEBERT, INC. PP. 93-101 DOI: 10.1089/PHO.2015.4015 ["QUANTUM LEAP" IN PHOTOBIMODULATION THERAPY USHERS IN A NEW GENERATION OF LIGHT-BASED TREATMENTS FOR CANCER AND OTHER COMPLEX DISEASES: PERSPECTIVE AND MINI-REVIEW](#). LUIS SANTANA-BLANK, MD, ELIZABETH RODRÍGUEZ-SANTANA, MD, KARIN E. SANTANA-RODRÍGUEZ, BS AND HEBERTO REYES, MD.
5. NIH PUBLIC ACCESS. AVAILABLE IN PMC 2014 AUGUST 08. SEMIN CUTAN MED SURG. FINAL EDITED FORM AS: SEMIN CUTAN MED SURG. 2013 MARCH ; 32(1): 41-52. [LOW-LEVEL LASER \(LIGHT\) THERAPY \(LLLT\) IN SKIN: STIMULATING, HEALING, RESTORING](#). PINAR AVCI, MD, ASHEESH GUPTA, PHD, MAGESH SADASIVAM, MTECH, DANIELA VECCHIO, PHD, ZEEV PAM, MD, NADAV PAM, MD, AND MICHAEL R HAMBLIN, PHD.
6. JPN J OPHTHALMOL. 2003 NOV-DEC;47(6):578-86. - [DISPOSABLE EYELID-WARMING DEVICE FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION](#). MORI A, SHIMAZAKI J, SHIMMURA S, FUJISHIMA H, OGUCHI Y, TSUBOTA K.
7. JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS VOL. 30, NO. 2 (S1), 161-167 (2016) [EVALUATION OF LIGHT-EMITTING DIODE \(LED-835 NM\) APPLICATION OVER HUMAN GINGIVAL FIBROBLAST: AN IN VITRO STUDY](#). M. RONCATI, D. LAURITANO, F. CURA AND F. CARINCI.
8. LASER THERAPY JOURNAL 16.4: 189-197. [THE POSSIBILITY OF THE APPLICATION OF LOW REACTIVE LEVEL LASER THERAPY IN THE FIELD OF OPHTHALMOLOGY](#). TOSHIO OHSHIRO M.D., PH.D., TAKAFUMI OHSHIRO M.D., KATSUMI SASAKI M.D., SHUNJI FUJII M.D., YUKI TANIGUCHI M.D. AND MASARU YOSHIDA, KIYOFUMI TAKENOUCHE AND MITSUAKI KOHZUMA.
9. ACTA OPHTHALMOLOGICA: ABSTRACTS FROM THE 2015 EUROPEAN ASSOCIATION FOR VISION AND EYE RESEARCH CONFERENCE ABS15-0376: [APPLICATION OF LOW-LEVEL LASER THERAPY \(LLLT\) IN PATIENTS WITH RETINITIS PIGMENTOSA \(RP\)](#). K. KOEV.